Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Delavirdine
Drug ID BADD_D00603
Description A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Indications and Usage For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted
Marketing Status approved
ATC Code J05AG02
DrugBank ID DB00705
KEGG ID D07782
MeSH ID D020008
PubChem ID 5625
TTD Drug ID D0G6SD
NDC Product Code Not Available
UNII DOL5F9JD3E
Synonyms Delavirdine | Rescriptor | U-90152 | U 90152 | U90152 | U-90152S | U 90152S | U90152S | Delavirdine Mesylate | Mesylate, Delavirdine
Chemical Information
Molecular Formula C22H28N6O3S
CAS Registry Number 136817-59-9
SMILES CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tinnitus04.04.01.002; 17.04.07.004--
Tongue disorder07.14.01.002--Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.007--Not Available
Tooth abscess11.01.04.003; 07.09.01.003--Not Available
Toothache07.09.06.001--
Toxic epidermal necrolysis11.07.01.006; 10.01.01.006; 23.03.01.008; 12.03.01.015--
Tremor17.01.06.002--
Tuberculosis11.04.01.006--Not Available
Ulcer08.03.06.001--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria23.04.02.001; 10.01.06.001--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Viral infection11.05.04.001--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
Weight increased13.15.01.006--
Fat redistribution14.08.04.002--Not Available
Contusion15.03.05.007; 24.07.06.001; 23.03.11.002; 12.01.06.001--
Respiratory tract congestion22.02.07.003--Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Depressive symptom19.15.02.003--Not Available
Affect lability19.04.01.001--Not Available
Cognitive disorder19.21.02.001; 17.03.03.003--
Nuchal rigidity17.05.02.006; 15.05.04.005--Not Available
Vasodilation procedure25.03.01.001--Not Available
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages